HONG KONG / BEIJING (Reuters) – China’s national pharmaceutical organization (Sinopharm) said Wednesday that knowledge of the complex and large-scale clinical trials of its unit’s COVID-19 vaccine is “better than expected. “
Sinopharm’s unit, China National Biotec Group (CNBG), has transferred two vaccine applicants to outdoor Phase 3 clinical trials in China in several countries, adding the United Arab Emirates, Bahrain and Egypt, involving more than 50,000 participants in total.
Rehearsals are coming to an end, Sinopharm said on a Chinese social network WeChat.
It provided key points on better-than-expected knowledge, nor did it specify which candidate vaccine the knowledge was generated from.
(Report via Meg Shen and Roxanne Liu; Editing through Andrew Heavens)